Analysis of killer cell immunoglobulin-like receptor genotypes in acute and chronic myeloid leukemia
Öz
Purpose: Interactions between natural killer (NK)-expressed killer-cell immunoglobulin-like receptors (KIRs) and Major Histocompatibility Complex (MHC) class I molecules determine immune responses against tumour cells. Previous studies have shown that alloreactive potential of NK cells provide a promising treatment option for patients with hematological malignancies. The aim of this study was to investigate the KIR genes and genotypes in patients with acute myeloid leukemia (AML) and chronic myeloid leukemias (CML).
Materials and Methods: We investigated the frequency of KIR in AML (n=34) and CML (n=56) patients from Southern (Mediterranean) region of Türkiye and compared the results with 100 healthy controls. Polymerase chain reaction (PCR) and sequence-specific oligonucleotide (SSO) methods were used to identify KIR genes in peripheral blood samples.
Results: We observed an increased frequency of inhibitory KIR2DL3 in myeloid leukemia patients (91.3%) compared to controls (78%). Additionally, the frequency of KIR2DL3 was significantly higher in CML patients compared to controls (93.5% vs. 78%,). Notably, there was also a decreased incidence of inhibitory KIR2DL2 and its activating counterpart KIR2DS2 in CML patients compared to controls (34.8% vs. 52%, both, respectively). Additionally, there was a tendency for inhibitory KIR genes to predominate in patients with myeloid leukemia.
Conclusion: Our findings suggest a potential role for the KIR genes in the pathogenesis of myeloid leukemia. Further studies are needed to investigate the relationships between KIR gene polymorphisms and human leukocyte antigen (HLA) ligands in leukemia and the impact of NK cell responses on clinical outcomes.
Anahtar Kelimeler
Destekleyen Kurum
Scientific Research Projects were supported by Çukurova University.
Etik Beyan
The study was approved by the institutional review board of Çukurova University.
Kaynakça
- Kulkarni S, Martin MP, Carrington M. The yin and yang of HLA and KIR in human disease. Semin Immunol. 2008;20:343-52.
- Agnello L, Masucci A, Tamburello M, Facciotti F, Santoni A, Moretta L et al. The role of killer Ig-like receptors in diseases from A to Z. Int J Mol Sci. 2025;26:3242.
- Purdy AK, Campbell KS. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther. 2009;8:2211-20.
- Zitvogel L, Apetoh L, Ghiringhelli F, Smyth MJ, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59-73.
- Lotzova E, Savary CA, Herberman RB. Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leuk Res. 1987;11:1059-66.
- Ruggeri L, Capanni M, Casucci M, Aversa F, Moretta L, Moretta A et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333-9.
- Middleton D, Diler AS, Meenagh A, Farrell L, Curran MD, Barnardo MC et al. Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia. Tissue Antigens. 2009;73:553-60.
- Varbanova VP, Mihailova S, Naumova E, Pavlova E, Ivanova M, Kostova E et al. Certain killer immunoglobulin-like receptor (KIR)/KIR HLA class I ligand genotypes influence natural killer antitumor activity in myelogenous leukemia but not in acute lymphoblastic leukemia: a case control leukemia association study. Turk J Haematol. 2019;36:238-46.
- Ali S, Sergeant R, O'Brien SG, Goldman JM, Melo JV, Apperley JF et al. Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. Blood. 2012;120:697-8.
- Marin D, Gabriel IH, Ahmad S, Mahmud N, Agrawal V, Rea D et al. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia. 2012;26:296-302.
